Biotech | October 29, 2021
Merck expands capacity for Antibody Drug Conjugate (ADC), therapies
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
By combining Innovaccer's Data Activation Platform with HCL's robust healthcare data accelerator (hDATA) suite, organizations can enable patient-centricity, cost-optimization and compliance
The company plans to raise US $ 15 million
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
Subscribe To Our Newsletter & Stay Updated
